AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Efficacy of 7 Days Versus 14 Days of Antibiotic Therapy for Acute Pyelonephritis in Kidney Transplant Recipients, a Multicentre Randomized Non-inferiority Trial.

RecruitingPhase 3Ages 18 Years - anyAllAssistance Publique - Hôpitaux de Paris
💬

In plain words

What the trial is, and whether it could suit you

Infections are a major cause of morbidity and mortality in solid organ transplant recipients. In kidney transplant recipients (KTR) urinary tract infection (UTI) represent 45-72% of all infections, and 30% of all hospitalizations for sepsis. Acute transplant pyelonephritis are the most common complications occurring in more than 20% of patients, mainly in the first year after transplantation. They are associated with an increased risk of acute kidney rejection and long-term kidney graft dysfunction. Gram-negative bacteria, mainly E. coli, account for more than 70% of UTI in KTR. As those infections are favoured by urinary tract modifications/defects and immunosuppression, they are often recurrent and necessitate repeated courses of antibiotics. Selective pressure due to antibiotic consumption, along with frequent hospital admissions and immunosuppression, are well known risk factors for

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Age \>18 years KTR * APN defined by: fever (T°≥38°C) (with or without clinical signs and/or symptoms of UTI) and pyuria (≥10\^4 white blood cells/mL or ≥10/mm3) and positive urine culture (uropathogen ≥10\^3 CFU/mL susceptible to the empirically administrated antibiotic) * No confirmed or suspected febrile non urinary bacterial infection * No urologic/renal complication at baseline imaging (abscess, obstruction...) * Favourable early response to antibiotic treatment:48 to 60 hours after the first dose of antibiotic effective against the causative uropathogen) defined by: T°\<38°C and improvement (or resolution) of signs and/or symptoms of urinary tract infection if present at diagnosis * Written informed consent Exclusion Criteria: * Severe or complicated condition * Any rapidly progressing disease or immediately life-threatening illness, including, but not limited to, septic shock, current or impeding respiratory failure, acute heart or liver failure * Admission or stay in intensive care unit at baseline * Obstruction of the urinary tract * Renal, perinephric or prostatic abscess * Prior inclusion in this study * Current participation to another interventional study * Dual antibiotic therapy (prophylactic antibiotic such as cotrimoxazole allowed) (only 1 dose of aminoside is allowed before randomization) * First month post transplantation * Current indwelling catheter (including bladder catheter, ureteral stents, percutaneous nephrostomy tubes) * Neurogenic bladder * Enterocystoplasty * Immunodeficiency or immunosuppressive therapy not related to kidney transplantation including hematologic malignancy, cancer, asplenia, neutropenia\<500 neutrophils/mm3 * Pregnancy, breastfeeding * Hypersensitivity or previous severe adverse drug reaction to the antibiotic therapy * Unable or unwilling, in the judgment of the investigator, to comply with the protocol * Life expectancy\<1 month * Patient under legal guardianship or without healthcare coverage * Homeless patient * Women with childbearing potential not using adequate contraception
💊

What it tests

  • Short antibiotic treatment
  • Usual antibiotic treatment
📍

Where

9 sites
CHU Bordeaux
Bordeaux, France
Hôpital Foch
Boulogne-Billancourt, France
CHU Mondor
Créteil, France
CHU Lyon
Lyon, France
CHU Nantes
Nantes, France
CHU Kremlin-Bicêtre
Paris, France
CHU Necker
Paris, France
CHU Saint Louis
Paris, France

…and 1 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy